Evidence map›Paper›PMID 28593105›Full record

ArticleJournal of neurology and neuroscience2017

Photobiomodulation with Near Infrared Light Helmet in a Pilot, Placebo Controlled Clinical Trial in Dementia Patients Testing Memory and Cognition.

Marvin H Berman, James P Halper, Trent W Nichols, H Jarrett, Alan Lundy, Jason H Huang

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in Journal of neurology and neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 71 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 6 pooled it
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01059877 nacompletednot on this map

Assessing the Effect of 1072nm Infrared (IR) Phototherapy on the Behavioral and Cognitive Symptoms Associated With Early and Mid-stage Dementia: a Randomized Placebo-controlled Clinical Trial.

TypeinterventionalSponsorQuietmind FoundationRan2010 to 2012Enrolled11ConditionsDementiaArms1072nm infrared Photobiomodulation, Photobiomodulation SIMULATED
NCT03405662 nacompletednot on this mapstarted 2018, after this paper: background citation

Examining the Impact of Photobiomodulation on Cognition, Behavior, and Biomarkers of Alzheimer's Disease

TypeinterventionalSponsorUniversity of California, San FranciscoRan2018 to 2021Enrolled23ConditionsAlzheimer DiseaseArmsVielight Neuro Gamma, Sham Vielight Neuro Gamma
3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 6 syntheses or guidelines pooled it, 169 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Efficacy of Transcranial Photobiomodulation on Depressive Symptoms: A Meta-Analysis.Photobiomodulation, photomedicine, and laser surgery · 2023
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Photobiomodulation improves the frontal cognitive function of older adults.International journal of geriatric psychiatry · 2019
    Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Marvin H BermanP.I. Quietmind Foundation, 1016 Greenwood Ave, Wyncote PA 19095, USA.
James P HalperP.I. Quietmind Foundation, 1016 Greenwood Ave, Wyncote PA 19095, USA.
Trent W NicholsBoard, Quietmind Foundation, CNDD Hanover PA 17331, USA.
H JarrettBoard, Quietmind Foundation, CNDD Hanover PA 17331, USA.
Alan LundyBoard, Quietmind Foundation, CNDD Hanover PA 17331, USA.
Jason H HuangDepartment of Neurosurgery, Baylor Scott and White, Temple, Texas 76502, USA.
Quietmind Foundation · US

Funding

Use of Engineered Nervous Tissue Constructs to Repair Extensive Nerve InjuryR01NS067435 · NINDS · UNIVERSITY OF ROCHESTER · PI HUANG, JASON H. · 2010 to 2014
$1.6M
NINDS NIH HHS R01 NS067435
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a common, chronic expensive debilitating neurodegenerative disease with no current treatments to prevent the physical deterioration of the brain and the consequent cognitive deficits. The current pathophysiology of Alzheimer's disease is the accumulation of neurofibrillary tangles (NFTs) of hyperphosphorylated tau protein and amyloid-beta (Aβ) plaques. Antibody therapy of Tau and Amyloid beta, vaccines and other methods to decrease Tau and or Amyloid have not been successful after considerable pharmaceutical and biotech efforts. For example, Eli Lilly announced a major change to its closely watched clinical trial for the Alzheimer's drug solanezumab which failed to reach statistical significance. Recently, a report on animal models using photomodulation with near infrared light to treat AD pathology in K369I tau transgenic model (K3) l engineered to develop neurofibrillary tangles, and the APPs/PSEN1dE9 transgenic model (APP/PS1) to develop amyloid plaques. Mice were treated with NIR 20 times over a four-week period and NIR treatment (600-1000 nm) was associated with a reduction in the size and number of amyloid-β plaques in the neocortex and hippocampus. We now report a small pilot double blind, placebo-controlled trial (n=11) 6 active, 3 controls and 2 dropouts assessing the effect of 28 consecutive, sixminute transcranial sessions of near infrared (NIR) stimulation using 1060-1080 nm light emitting diodes. Subjects were independently diagnosed with dementia conducted in an outpatient behavioral healthcare clinic. IRB approval was obtained through the Quietmind Foundation's institutional review Board (IRB). Results showed changes in executive functioning; clock drawing, immediate recall, praxis memory, visual attention and task switching (Trails A&B) as well as a trend of improved EEG amplitude and connectivity measures. Neuroplasticity has also been reported with NIR light stimulation and mitochondrial enhancement.

Indexed as

Alzheimer’s diseaseCognitionMemoryPhotobiomodulation

Identifiers

PMID28593105
PMCPMC5459322
OpenAlexW2595728361

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.